A Curcumin Analog, 3,5-Bis(2′-ethoxybenzylidene)-piperidine-4-one (E145), Suppresses NF-κB Signaling to Inhibit Breast Cancer Growth and Metastasis
Biological and Pharmaceutical Bulletin · 28.07.2026 · 49 (7) · 1174-1181
DOI: 10.1248/bpb.b26-00307 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, erschienen am 28.07.2026. Verfasst von Sana Jabbar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Section of Host Defences, Institute of Natural Medicine, University of Toyama, Toyama 930-0194, Japan. Hauptthemen laut MEDLINE: Curcumin, Breast Neoplasms, NF-kappa B, Antineoplastic Agents. Die Arbeit nennt 46 Literaturangaben.
Abstract (Originalsprache)
Curcumin is a naturally occurring bioactive compound with well-characterized anti-inflammatory and antitumor properties; however, its clinical utility is limited by poor bioavailability and chemical instability. To overcome these limitations, various curcumin analogs have been developed. In this study, we investigated the antitumor and antimetastatic effects of 3,5-bis(2′-ethoxybenzylidene)-piperidine-4-one (E145), a monocarbonyl curcumin analog, with a particular focus on its ability to inhibit nuclear factor-kappaB (NF-κB) signaling in breast cancer cells. We first evaluated the effects of E145 on cell proliferation in murine 4T1 and human MDA-MB-231 breast cancer cell lines. E145 inhibited cell proliferation in a dose-dependent manner and suppressed phosphorylation of the NF-κB p65 subunit. Furthermore, E145 blocked tumor necrosis factor alpha–induced NF-κB activation by inhibiting both p65 phosphorylation and nuclear translocation. Consistently, E145 reduced the expression of NF-κB–regulated pro-tumorigenic factors, including vascular endothelial growth factor, matrix metalloproteinase-9, interleukin-1β (IL-1β), and IL-6. Functional assays demonstrated that E145 markedly suppressed the migration and invasion of breast cancer cells in vitro. In addition, experimental lung metastasis assays revealed that E145 treatment significantly reduced metastatic colonization of 4T1 cells in vivo. Collectively, these findings indicate that E145 exerts potent antimetastatic effects by inhibiting cell-intrinsic NF-κB activation and downstream inflammatory mediators. These results suggest that E145 is a promising therapeutic candidate for targeting NF-κB–driven breast cancer progression and metastasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Host Defences, Institute of Natural Medicine, University of Toyama, Toyama 930-0194, Japan.
- Department of Cancer Cell Biology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan.
- Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta 55281, Indonesia.
- Curcumin Research Center, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta 55281, Indonesia.
Zitieren
APA
Jabbar, S., Zhou, Y., Kobayashi, S., He, K., Ucche, S., Ritmaleni, Sasaki, S. I., & Hayakawa, Y. (2026). A Curcumin Analog, 3,5-Bis(2′-ethoxybenzylidene)-piperidine-4-one (E145), Suppresses NF-κB Signaling to Inhibit Breast Cancer Growth and Metastasis. Biological and Pharmaceutical Bulletin, 49(7), 1174-1181. https://doi.org/10.1248/bpb.b26-00307
Vancouver
Jabbar S, Zhou Y, Kobayashi S, He K, Ucche S, Ritmaleni, et al. A Curcumin Analog, 3,5-Bis(2′-ethoxybenzylidene)-piperidine-4-one (E145), Suppresses NF-κB Signaling to Inhibit Breast Cancer Growth and Metastasis. Biological and Pharmaceutical Bulletin. 2026;49(7):1174-1181. doi:10.1248/bpb.b26-00307
BibTeX
@article{Jabbar2026,
author = {Jabbar, Sana and Zhou, Yue and Kobayashi, Seiya and He, Ka and Ucche, Sisca and Ritmaleni and Sasaki, So-Ichiro and Hayakawa, Yoshihiro},
title = {A Curcumin Analog, 3,5-Bis(2′-ethoxybenzylidene)-piperidine-4-one (E145), Suppresses NF-κB Signaling to Inhibit Breast Cancer Growth and Metastasis},
journal = {Biological and Pharmaceutical Bulletin},
year = {2026},
volume = {49},
number = {7},
pages = {1174--1181},
doi = {10.1248/bpb.b26-00307}
}
EUVIMED